Barclays Cuts Clorox (NYSE:CLX) Price Target to $130.00

Clorox (NYSE:CLX) had its target price lowered by stock analysts at Barclays from $139.00 to $130.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “underweight” rating on the stock. Barclays‘s price target would suggest a potential downside of 18.91% from the stock’s current price.

Several other research analysts have also recently weighed in on the stock. Wells Fargo & Company upgraded shares of Clorox from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $155.00 to $157.00 in a research report on Tuesday, January 7th. StockNews.com lowered shares of Clorox from a “buy” rating to a “hold” rating in a report on Sunday, January 5th. JPMorgan Chase & Co. lifted their price objective on shares of Clorox from $167.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday. Evercore ISI reduced their target price on Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research note on Monday, October 14th. Finally, Jefferies Financial Group raised Clorox from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $187.00 in a research note on Tuesday, October 1st. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Clorox has an average rating of “Hold” and a consensus price target of $156.54.

Clorox Stock Down 0.1 %

Shares of NYSE:CLX opened at $160.31 on Friday. The firm has a fifty day moving average price of $164.25 and a two-hundred day moving average price of $156.38. The company has a market cap of $19.84 billion, a price-to-earnings ratio of 55.86, a PEG ratio of 2.90 and a beta of 0.42. The company has a debt-to-equity ratio of 11.08, a current ratio of 1.00 and a quick ratio of 0.62. Clorox has a one year low of $127.60 and a one year high of $171.37.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.50. The company had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.64 billion. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company earned $0.49 earnings per share. Analysts anticipate that Clorox will post 6.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Clorox

A number of hedge funds have recently modified their holdings of CLX. State Street Corp grew its stake in shares of Clorox by 3.1% in the third quarter. State Street Corp now owns 8,182,109 shares of the company’s stock worth $1,332,947,000 after purchasing an additional 245,525 shares during the last quarter. Mizuho Securities USA LLC increased its stake in shares of Clorox by 46,877.8% during the third quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after buying an additional 4,490,421 shares during the period. Geode Capital Management LLC raised its holdings in shares of Clorox by 1.1% during the third quarter. Geode Capital Management LLC now owns 3,028,333 shares of the company’s stock valued at $491,713,000 after acquiring an additional 33,970 shares in the last quarter. Stifel Financial Corp lifted its stake in Clorox by 1.7% in the third quarter. Stifel Financial Corp now owns 2,334,826 shares of the company’s stock worth $380,370,000 after acquiring an additional 37,967 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in Clorox by 2.2% in the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock valued at $237,372,000 after acquiring an additional 31,510 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.